Efficient α and β

Fibroblast activation protein-α Programmed death-ligand 1 Single domain antibodies Targeted radionuclide therapy

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
06 Sep 2024
Historique:
received: 28 06 2024
accepted: 01 09 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 5 9 2024
Statut: aheadofprint

Résumé

Targeted radionuclide therapy (TRT) is a cancer treatment with relative therapeutic efficacy across various cancer types. We studied the therapeutic potential of TRT using fibroblast activation protein-α (FAP) targeting sdAbs (4AH29) labelled with We studied the biodistribution and tumour uptake of [ The biodistribution showed high tumour uptake of [ [

Identifiants

DOI: 10.1007/s00259-024-06914-4 PMID: 39237746
pubmed: 39237746
doi: 10.1007/s00259-024-06914-4
pii: 10.1007/s00259-024-06914-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Innoviris
ID : BRGRD44
Organisme : Vrije Universiteit Brussel
ID : SRP48
Organisme : Kom op tegen Kanker
ID : ANI304
Organisme : Kom op tegen Kanker
ID : ANI368
Organisme : Stichting Wetenschappelijk Onderzoek Oogziekenhuis
ID : G041721N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1S06622N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1801619N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 12H3619N
Organisme : Bijzonder Onderzoeksfonds UGent
ID : iBOF/23/043
Organisme : Eutopia Foundation
ID : OZR3808BOF

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Funeh CN, Bridoux J, Ertveldt T, De Groof TWM, Chigoho DM, Asiabi P, et al. Optimizing the Safety and Efficacy of Bio-radiopharmaceuticals for Cancer Therapy. Pharmaceutics. 2023;15. https://doi.org/10.3390/pharmaceutics15051378 .
Rondon A, Rouanet J, Degoul F. Radioimmunotherapy in Oncology: overview of the last decade clinical trials. Cancers (Basel). 2021;13. https://doi.org/10.3390/CANCERS13215570 .
Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–8. https://doi.org/10.1038/363446A0 .
doi: 10.1038/363446A0 pubmed: 8502296
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, et al. Emerging applications of nanobodies in cancer therapy. Int Rev Cell Mol Biol. 2022;369:143–99. https://doi.org/10.1016/bs.ircmb.2022.03.010 .
doi: 10.1016/bs.ircmb.2022.03.010 pubmed: 35777863
D’Huyvetter M, De Vos J, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, et al. Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising candidate for HER2-Targeted Radionuclide Therapy in breast Cancer patients. J Nucl Med. 2021;62:1097–105. https://doi.org/10.2967/JNUMED.120.255679 .
doi: 10.2967/JNUMED.120.255679 pubmed: 33277400
Dekempeneer Y, Caveliers V, Ooms M, Maertens D, Gysemans M, Lahoutte T, et al. Therapeutic efficacy of 213Bi-labeled sdAbs in a preclinical model of Ovarian Cancer. Mol Pharm. 2020;17:3553–66. https://doi.org/10.1021/ACS.MOLPHARMACEUT.0C00580 .
doi: 10.1021/ACS.MOLPHARMACEUT.0C00580 pubmed: 32787284
Ertveldt T, De Beck L, De Ridder K, Locy H, de Mey W, Goyvaerts C, et al. Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled single domain antibodies induces distinct Immune signatures in a mouse Melanoma Model. Mol Cancer Ther. 2022;21:1136–48. https://doi.org/10.1158/1535-7163.MCT-21-0791 .
doi: 10.1158/1535-7163.MCT-21-0791 pubmed: 35499391 pmcid: 9377759
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, De, et al. Targeted α-Therapy using 225Ac radiolabeled single-domain antibodies induces Antigen-Specific Immune responses and instills Immunomodulation both systemically and at the Tumor Microenvironment. J Nucl Med. 2023;64:751–8. https://doi.org/10.2967/jnumed.122.264752 .
doi: 10.2967/jnumed.122.264752 pubmed: 37055223
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, et al. Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12041017 .
Puttemans J, Stijlemans B, Keyaerts M, Meeren S, Vander, Renmans W, Fostier K, et al. The Road to Personalized Myeloma Medicine: patient-specific single-domain antibodies for anti-idiotypic Radionuclide Therapy. Mol Cancer Ther. 2022;21:159–69. https://doi.org/10.1158/1535-7163.MCT-21-0220 .
doi: 10.1158/1535-7163.MCT-21-0220 pubmed: 34667109
Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, et al. Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2022;49:871–80. https://doi.org/10.1007/S00259-021-05554-2 .
doi: 10.1007/S00259-021-05554-2 pubmed: 34537893
Dekempeneer Y, Massa S, Santens F, Navarro L, Berdal M, Lucero MM, et al. Preclinical evaluation of a Radiotheranostic single-domain antibody against fibroblast activation protein α. J Nucl Med. 2023;64:1941–8. https://doi.org/10.2967/jnumed.123.266381 .
doi: 10.2967/jnumed.123.266381 pubmed: 38040444
Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57. https://doi.org/10.1038/S41388-018-0275-3 .
doi: 10.1038/S41388-018-0275-3 pubmed: 29720723 pmcid: 6092565
De Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E, et al. CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8 + T cells and PD-L1 expression in multiple myeloma. Oncoimmunology. 2021;10. https://doi.org/10.1080/2162402X.2021.2000699 .
Novruzov E, Mori Y, Alavi A, Giesel FL. The impact of FAP imaging in lung cancer and beyond: a new chapter. Eur Radiol. 2024;34:1946–7. https://doi.org/10.1007/S00330-023-10398-5 .
doi: 10.1007/S00330-023-10398-5 pubmed: 37943314
Lepareur N, Ramée B, Mougin-Degraef M, Bourgeois M. Clinical advances and perspectives in targeted Radionuclide Therapy. Pharmaceutics. 2023;15. https://doi.org/10.3390/PHARMACEUTICS15061733 .
Kerr CP, Grudzinski JJ, Nguyen TP, Hernandez R, Weichert JP, Morris ZS. Developments in combining targeted Radionuclide therapies and immunotherapies for Cancer Treatment. Pharmaceutics. 2022;15. https://doi.org/10.3390/PHARMACEUTICS15010128 .
Tanaka T, Delong PA, Amin K, Henry A, Kruklitis R, Kapoor V, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg. 2005;241:168–78. https://doi.org/10.1097/01.SLA.0000149427.84712.D9 .
doi: 10.1097/01.SLA.0000149427.84712.D9 pubmed: 15622005 pmcid: 1356860
De Ridder K, Tung N, Werle J-T, Karpf L, Awad RM, Bernier A, et al. Novel 3D lung tumor spheroids for Oncoimmunological assays. Adv Nanobiomed Res. 2022;2. https://doi.org/10.1002/anbr.202100124 .
D’Huyvetter M, Xavier C, Caveliers V, Lahoutte T, Muyldermans S, Devoogdt N. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Deliv. 2014;11:1939–54. https://doi.org/10.1517/17425247.2014.941803 .
doi: 10.1517/17425247.2014.941803 pubmed: 25035968 pmcid: 4245996
Breckpot K, Dullaers M, Bonehill A, Van Meirvenne S, Heirman C, De Greef C, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med. 2003;5:654–67. https://doi.org/10.1002/jgm.400 .
doi: 10.1002/jgm.400 pubmed: 12898635
Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:153535002003031. https://doi.org/10.1162/15353500200303133 .
doi: 10.1162/15353500200303133
D’Huyvetter M, De Vos J, Xavier C, Pruszynski M, Sterckx YGJ, Massa S, et al. 131I-labeled Anti-HER2 camelid sdAb as a Theranostic Tool in Cancer Treatment. Clin Cancer Res. 2017;23:6616–28. https://doi.org/10.1158/1078-0432.CCR-17-0310 .
doi: 10.1158/1078-0432.CCR-17-0310 pubmed: 28751451 pmcid: 5668161
Rodak M, Dekempeneer Y, Wojewodzka M, Caveliers V, Covens P, Miller BW, et al. Preclinical evaluation of 225Ac-Labeled single-domain antibody for the treatment of HER2pos Cancer. Mol Cancer Ther. 2022;21:1835–45. https://doi.org/10.1158/1535-7163.MCT-21-1021 .
doi: 10.1158/1535-7163.MCT-21-1021 pubmed: 36129807 pmcid: 9716241
Lemaire M, D’Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic nanobodies. Leukemia. 2014;28:444–7. https://doi.org/10.1038/LEU.2013.292 .
doi: 10.1038/LEU.2013.292 pubmed: 24166214
Kratochwil C, Bruchertseifer F, Giesel F, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-DOTATOC – an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015;56(S3):1232.
Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted α-Therapy of metastatic castration-resistant prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017;58:1624–31. https://doi.org/10.2967/JNUMED.117.191395 .
doi: 10.2967/JNUMED.117.191395 pubmed: 28408529
Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651–67. https://doi.org/10.1007/S00259-022-05842-5 .
doi: 10.1007/S00259-022-05842-5 pubmed: 35608703 pmcid: 9399058
Privé BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906–18. https://doi.org/10.1007/S00259-023-06144-0 .
doi: 10.1007/S00259-023-06144-0 pubmed: 36813980 pmcid: 10199876
Ferdinandus J, Costa PF, Kessler L, Weber M, Hirmas N, Kostbade K, et al. Initial clinical experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid tumors: a Case Series of 9 patients. J Nucl Med. 2022;63:727–34. https://doi.org/10.2967/JNUMED.121.262468 .
doi: 10.2967/JNUMED.121.262468 pubmed: 34385340 pmcid: 9051597
Kuyumcu S, Kovan B, Sanli Y, Buyukkaya F, Has Simsek D, Özkan ZG, et al. Safety of fibroblast activation protein-targeted Radionuclide Therapy by a low-dose Dosimetric Approach using 177Lu-FAPI04. Clin Nucl Med. 2021;46:641–6. https://doi.org/10.1097/RLU.0000000000003667 .
doi: 10.1097/RLU.0000000000003667 pubmed: 33883494
Rao Z, Zhang Y, Liu L, Wang M, Zhang C. [177Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases. Eur J Nucl Med Mol Imaging. 2023;50:1266–7. https://doi.org/10.1007/S00259-022-06048-5 .
doi: 10.1007/S00259-022-06048-5 pubmed: 36418590
Olson B, Li Y, Lin Y, Liu ET, Patnaik A. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8:1358–65. https://doi.org/10.1158/2159-8290.CD-18-0044 .
doi: 10.1158/2159-8290.CD-18-0044 pubmed: 30309862 pmcid: 8725605
Potluri HK, Ferreira CA, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle JW, et al. Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. J Immunother Cancer. 2022;10. https://doi.org/10.1136/JITC-2022-005060 .
Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2018;7. https://doi.org/10.1080/2162402X.2017.1364828 .
Lecocq Q, Keyaerts M, Devoogdt N, Breckpot K. The Next-Generation Immune Checkpoint LAG-3 and its therapeutic potential in Oncology: Third Time’s a Charm. Int J Mol Sci. 2021;22:1–17. https://doi.org/10.3390/IJMS22010075 .
doi: 10.3390/IJMS22010075
Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11. https://doi.org/10.1038/S41467-020-18570-X .
Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. PD-L1 interacts specifically with B7-1 to inhibit T cell proliferation. Immunity. 2007;27:111. https://doi.org/10.1016/J.IMMUNI.2007.05.016 .
doi: 10.1016/J.IMMUNI.2007.05.016 pubmed: 17629517 pmcid: 2707944
Lee EJ, Jang GY, Lee SE, Lee Jwon, Han HD, Park YM, et al. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody. Immunol Lett. 2021;240:137–48. https://doi.org/10.1016/j.imlet.2021.10.006 .
doi: 10.1016/j.imlet.2021.10.006 pubmed: 34710507
Awad RM, Breckpot K. Novel technologies for applying immune checkpoint blockers. Int Rev Cell Mol Biol. 2024;382:1–101. https://doi.org/10.1016/BS.IRCMB.2023.03.003 .
doi: 10.1016/BS.IRCMB.2023.03.003 pubmed: 38225100
Konen JM, Wu H, Gibbons DL. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities. Trends Pharmacol Sci. 2024;45:520–36. https://doi.org/10.1016/J.TIPS.2024.04.006 .
doi: 10.1016/J.TIPS.2024.04.006 pubmed: 38744552
Poty S, Ordas L, Dekempeneer Y, Parach AA, Navarro L, Santens F, et al. Optimizing the therapeutic index of sdab-based radiopharmaceuticals using pretargeting. Annual Congress of the European Association of Nuclear Medicine October 15–19, 2022 Barcelona, Spain. Eur J Nucl Med Mol Imaging. 2022;49(Suppl 1):1–751. https://doi.org/10.1007/s00259-022-05924-4 .
doi: 10.1007/s00259-022-05924-4

Auteurs

Hannelore Ceuppens (H)

Vrije Universiteit Brussel, Department of Biomedical Sciences, Translational Oncology Research Center, Laboratory for Molecular and Cellular Therapy, Laarbeeklaan 103. Building E, Brussels, 1090, Belgium. Hannelore.Ceuppens@vub.be.
ORCID: 0000-0003-0187-4204

Ana Rita Pombo Antunes (AR)

Precirix NV/SA, Burg. Etienne Demunterlaan 3, Brussels, B-1090, Belgium.

Laurent Navarro (L)

Precirix NV/SA, Burg. Etienne Demunterlaan 3, Brussels, B-1090, Belgium.

Thomas Ertveldt (T)

Vrije Universiteit Brussel, Molecular Imaging and Therapy Research Group, Laarbeeklaan 103/K, Brussels, 1090, Belgium.

Marion Berdal (M)

Precirix NV/SA, Burg. Etienne Demunterlaan 3, Brussels, B-1090, Belgium.

Surasa Nagachinta (S)

Precirix NV/SA, Burg. Etienne Demunterlaan 3, Brussels, B-1090, Belgium.

Kirsten De Ridder (K)

Vrije Universiteit Brussel, Department of Biomedical Sciences, Translational Oncology Research Center, Laboratory for Molecular and Cellular Therapy, Laarbeeklaan 103. Building E, Brussels, 1090, Belgium.

Tony Lahoutte (T)

Vrije Universiteit Brussel, Molecular Imaging and Therapy Research Group, Laarbeeklaan 103/K, Brussels, 1090, Belgium.
Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel (UZ Brussel), Nuclear Medicine Department, Laarbeeklaan 101, Brussels, 1090, Belgium.

Marleen Keyaerts (M)

Vrije Universiteit Brussel, Molecular Imaging and Therapy Research Group, Laarbeeklaan 103/K, Brussels, 1090, Belgium.
Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel (UZ Brussel), Nuclear Medicine Department, Laarbeeklaan 101, Brussels, 1090, Belgium.

Nick Devoogdt (N)

Vrije Universiteit Brussel, Molecular Imaging and Therapy Research Group, Laarbeeklaan 103/K, Brussels, 1090, Belgium.

Cleo Goyvaerts (C)

Vrije Universiteit Brussel, Molecular Imaging and Therapy Research Group, Laarbeeklaan 103/K, Brussels, 1090, Belgium.

Matthias D'Huyvetter (M)

Precirix NV/SA, Burg. Etienne Demunterlaan 3, Brussels, B-1090, Belgium. Matthias.Dhuyvetter@precirix.com.
Vrije Universiteit Brussel, Molecular Imaging and Therapy Research Group, Laarbeeklaan 103/K, Brussels, 1090, Belgium. Matthias.Dhuyvetter@precirix.com.

Karine Breckpot (K)

Vrije Universiteit Brussel, Department of Biomedical Sciences, Translational Oncology Research Center, Laboratory for Molecular and Cellular Therapy, Laarbeeklaan 103. Building E, Brussels, 1090, Belgium. Karine.Breckpot@vub.be.

Classifications MeSH